Onco-Summaries: Daily Oncology Updates at a Glance

19/08/2025

First-line Opdivo + Yervoy received approval in Canada for CRC and HCC patients (Ref)

Health Canada approved Bristol Myers Squibb's nivolumab (Opdivo; anti-PD-1) + ipilimumab (Yervoy; anti-CTLA-4) for the first-line treatment of adult patients with:

• Unresectable or metastatic MSI-H/dMMR colorectal cancer, and

• Unresectable or advanced hepatocellular carcinoma

The approvals are based on results from the pivotal Phase 3 CheckMate-8HW and CheckMate-9DW trials, respectively.

Antengene Corporation's ATG-022 (CLDN18.2 ADC) received the Breakthrough Therapy designation for GC/GEJ in China (Ref)

The CDE of China's NMPA granted the Breakthrough Therapy designation to Antengene Corporation's ATG-022 (CLDN18.2 ADC) for the treatment of CLDN18.2+ve, HER2-ve, unresectable or metastatic gastric or gastroesophageal junction cancer in patients who have received at least two prior lines of therapy.

• In the Phase 1/2 CLINCH trial, ATG-022 demonstrated significant antitumor activity and a favorable safety profile in gastric or gastroesophageal junction adenocarcinoma patients across high, low, and ultra-low CLDN18.2 expression levels